Morana Vojnic, MD, MBA, discusses vorasidenib in grade 2 IDH1/2-mutated glioma.
Morana Vojnic, MD, MBA
Advertisement
Morana Vojnic, MD, MBA, is the director of neuro-oncology at Rutgers Cancer Institute and the system leader for neuro oncology at RWJBarnabas Health.
Articles by Morana Vojnic, MD, MBA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer
2
KEYNOTE-D46 Trial Is Discontinued With Sacituzumab Govitecan Plus Pembrolizumab in PD-L1–High NSCLC
3
GU Cancer Experts Highlight the Most Impactful and Discussion-Worthy Data Presented at ASCO 2026
4
Subcutaneous Isatuximab Administered Via OBI Approved in EU for Multiple Myeloma
5